8 Related guidance

8.1 In August 2001, NICE issued the guidance on topotecan: National Institute for Clinical Excellence (2001), Guidance on the use of topotecan for the treatment of ovarian cancer. NICE Technology Appraisal Guidance No.28. London: National Institute for Clinical Excellence. Available from www.nice.org.uk

8.2 In July 2002, NICE issued guidance on the use of PLDH in ovarian cancer: National Institute for Clinical Excellence (2002), Guidance on the use of pegylated liposomal doxorubicin hydrochloride in the treatment of advanced ovarian cancer. NICE Technology Appraisal Guidance No. 45. London: National Institute for Clinical Excellence. Available from www.nice.org.uk.